Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (199)	4/10/2003 9:08:52 AM
From: tuck	Read Replies (1) \| Respond to of 447

>>8:10AM OSI Pharm: Lehman sees significant Tarceva trial risk (OSIP) 15.89: Lehman continues to believe that significant risk exists regarding Tarceva trials and advise investor caution in the near-term; OSIP's partner DNA said in yesterday's conference call that the data monitoring committee for the Tarceva front line NSCLC phase III trial had advised investigators to stop Tarceva maintenance dosing due to an unspecified safety signal. Target is $19.<< Cheers, Tuck